Rob Schroeder, a patient with hemophilia B describes his experience receiving gene therapy (etranacogene dezaparvovec).
Hemophilia B is a genetic bleeding disorder due to dysfunction or deficiency of coagulation Factor IX. People with this condition may bleed for longer periods of time after injury or surgery. They are also susceptible to spontaneous bleeding in muscles, joints, and organs. These symptoms can be extremely painful and, in some cases, life-threatening.
As Schroeder explains, his chronic condition required him to be dependent on regular Factor IX infusions. Following his experience in a clinical trial in which he was given etranacogene dezaparvovec, an adeno-associated virus five (AAV5)-based gene therapy, he no longer required infusions with Factor IX and is relatively pain-free. Mr. Schroeder also noted that gene therapy has reduced his concerns about future health insurance issues that could arise if he was still dependent on regular Factor IX infusions.
To learn more about hemophilia B and other rare hematological disorders, visit checkrare.com/diseases/hematologic-disorders/
